Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

QR Code

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Ioannis Avgerinos,1 Aris Liakos,1,2 Apostolos Tsapas,1–3 Eleni Bekiari1,2 1Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Diabetes Centre, Second Medical Department, Aristotle University of Thessal...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Avgerinos I, Liakos A, Tsapas A, Bekiari E
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2019
Sujets:	dapagliflozin sodium-glucose co-transporter 2 (sglt-2) inhibitors type 2 diabetes cardiovascular risk Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/e39976d9cd7b4b7fbd4e45ff5994375d
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
par: Nguyen T, et autres
Publié: (2020)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
par: Jadwiga Nessler
Publié: (2021)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
par: Kuecker CM, et autres
Publié: (2016)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
par: Santos Cavaiola T, et autres
Publié: (2018)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
par: Simes BC, et autres
Publié: (2019)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
par: Olga Yuryevna Sukhareva, et autres
Publié: (2016)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
par: Papakitsou I, et autres
Publié: (2019)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
par: Bonora BM, et autres
Publié: (2020)

Canagliflozin review – safety and efficacy profile in patients with T2DM
par: Jakher H, et autres
Publié: (2019)

Adjunctive therapy for glucose control in patients with type 1 diabetes
par: Harris K, et autres
Publié: (2018)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
par: Yu H, et autres
Publié: (2017)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
par: Fan Yang, et autres
Publié: (2020)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
par: Davies MJ, et autres
Publié: (2017)

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
par: Men P, et autres
Publié: (2020)

Empagliflozin in type 1 diabetes
par: Mathieu C, et autres
Publié: (2019)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
par: Ahmadieh H, et autres
Publié: (2017)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
par: Seko Y, et autres
Publié: (2018)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
par: Ito H, et autres
Publié: (2019)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
par: Shen L, et autres
Publié: (2021)

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
par: Scheerer MF, et autres
Publié: (2016)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
par: Kawarasaki S, et autres
Publié: (2020)

Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
par: Contreras,Álvaro, et autres
Publié: (2019)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
par: Schwartz SS, et autres
Publié: (2016)

Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice
par: Jiang YK, et autres
Publié: (2019)

Effects of coenzyme Q10 on cardiovascular and metabolic biomarkers in overweight and obese patients with type 2 diabetes mellitus: a pooled analysis
par: Huang H, et autres
Publié: (2018)

Vascular Age as a Cardiovascular Risk Marker in Asymptomatic Patients with Type 2 Diabetes
par: Palma CCSSV, et autres
Publié: (2020)

Attainment of recommended therapeutic targets of modifiable cardiovascular risk factors among individuals with type 2 diabetes mellitus screened at a diabetes clinic in Sri Lanka
par: Weerarathna TP, et autres
Publié: (2018)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
par: Stefan D. Anker
Publié: (2019)

The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
par: Hirai K, et autres
Publié: (2020)

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
par: Angelo Avogaro
Publié: (2018)

Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
par: Kwong-Man Ng, et autres
Publié: (2018)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
par: Le Floch J
Publié: (2010)

Statin on insulin and adiponectin levels: true or false prophecy?
par: Jonnalagadda VG, et autres
Publié: (2018)

Heart failure in diabetes: From an increased risk to a treatment target
par: Eberhard Standl
Publié: (2018)

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
par: Sergey V. Kakorin, et autres
Publié: (2016)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
par: Muhammad Afzal, et autres
Publié: (2021)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
par: Aurélie Pahud de Mortanges, et autres
Publié: (2021)

Second line therapy in type 2 diabetes: legacy effect activation
par: Ekaterina A. Shestakova
Publié: (2017)

Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
par: Hinnen D, et autres
Publié: (2019)

The Factors Influencing the Renal Glucose Threshold in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
par: Cui SS, et autres
Publié: (2021)